Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Stuart sees dry eye disease drug fail ph. 3 study, plans another
Stuart Therapeutics’ dry eye disease drug has failed to demonstrate it can increase tear production in a phase 3 test.
James Waldron
Jun 24, 2025 9:26am
How 'overenthusiasm' led to Big Pharma's risky $6B TIGIT gamble
Jun 13, 2025 8:00am
Merck KGaA sheds light on failed portion of phase 2 lupus trial
Jun 12, 2025 9:41am
Corcept unveils promising survival data from phase 2 ALS fail
Jun 5, 2025 8:21am
Vigil's rare brain disease drug flunks phase 2 study
Jun 4, 2025 9:45am
Sanofi's IL-33 drug fails COPD study
May 30, 2025 5:30am
